Empowering API Quality Enhancement! Medicilon Received the 'Best Collaboration Award' from Jingye Medicine & Chemical Co., Ltd

On the journey of drug development, each collaboration is a profound test of professional competence and a severe test of professionalism. Recently, Medicilon USA Corp. (Medicilon) is honored to have received a thank-you letter from Jingye Medicine & Chemical Co., Ltd (Jingye Medicine) and was awarded the "Best Collaboration Award". This not only recognizes the professional capabilities and service level of Medicilon, but also reflects the result of the joint efforts and tacit collaboration between the two parties.

Best Collaboration Award.webp

Medicilon and Jingye Medicine
Work together to overcome difficulties and achieve fruitful collaboration

Jingye Medicine, as a secondary safety production standardization enterprise for hazardous chemicals, continues to demonstrate outstanding professional capabilities and profound industry accumulation in the fields of pharmaceutical raw materials, pharmaceutical intermediates and CDMO project services. In collaboration with Jingye Medicine, the Medicilon team has always upheld professionalism, closely collaborating with Jingye Medicine's process and analysis teams to jointly face and successfully overcome a series of technical challenges in the research and development process, ultimately ensuring the smooth progress of the project.

Currently, Medicilon has been involved in five projects with Jingye Medicine, with three of them are under development. These successful collaboration cases not only demonstrate the outstanding capabilities of both parties in the pharmaceutical research and development field, but also establish a solid foundation for future in-depth collaboration between the two parties.

Medicilon one-stop API CDMO service platform

In the field of APIs, Medicilon currently possesses cGMP-compliant production lines for APIs that meet the requirements for IND filing in both the United States and China. From preclinical small-scale synthesis and process development to commercial production, Medicilon integrates deeply with the entire supply chain system of enterprises, including research and development, procurement, and production. The production scales could be flexibly adjusted ranging from milligrams to kilograms. Meanwhile, Medicilon possesses a rigorous and experienced analysis and quality inspection team, providing precise analysis services and strict quality control throughout the project.

The Medicilon's Process Department not only provides clients with services in the R&D, analysis testing, and stability research of generic drugs, but also offers services for the R&D, production, analysis testing, and stability research of innovative drugs in Phase I and Phase II clinical trials, gradually transitioning from R&D process development to industrial commercial production, and from CRO to CDMO.

About Jingye Medicine

Jingye Medicine & Chemical Co., Ltd. was established in 1998 in the Suzhou High-tech Zone Incubator, mainly producing APIs, pharmaceutical intermediates, and CDMO project services. The company covers an area of nearly 80 acres, currently employing 282 people, and owns 9 commercial production workshops, including 3 GMP workshops and 1 CDMO workshop. The main products include intermediates for Pemetrexed, Quetiapine Hydrochloride, Quetiapine Fumarate, Paroxetine Hydrochloride, and Sitagliptin intermediates. In 2008, the company passed the ISO9001 Quality Management System Certification, ISO14001 Environmental Management System Certification, and ISO18001 Occupational Health and Safety Management System Certification. In 2014, it obtained the Jiangsu Province Safety Standardization Level II Certification. In 2021, it obtained the Drug Production License. So far, the company has 36 high-tech products, applied for 25 invention patents, and obtained 15 authorized patents. In 2023, Jingye Medicine achieved a production value of RMB 230 million.

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

What is Toxicokinetics?

Toxicokinetics is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms toxicokinetics , pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...

阅读全文

Shanghai Medicilon Inc.

搜索此博客